FDA takes next step in new drug reorganization, including revamping oncology review

FDA announced the establishment of three new offices as part of a wide-ranging reorganization of the Center for Drug Evaluation and Review’s Office of New Drugs.

The new organization is flatter and includes new disease-focused divisions. It is intended to allow FDA to focus more relevant expertise on drug reviews, and to create opportunities for FDA staff to become scientific thought leaders in their disciplines. ...